Endoscopic sleeve gastroplasty (ESG) demonstrated cost-effectiveness compared to lifestyle modification in adults with class I/II obesity within a five-year horizon, achieving an incremental cost-effectiveness ratio of $23,432 per quality-adjusted life year (QALY). ESG remained cost-effective across sensitivity analyses and was dominant over longer timeframes. The findings suggest ESG as a viable treatment alternative for individuals with obesity, encouraging its consideration in commercial health plans for eligible patients.
Journal Article by Sharaiha RZ, Wilson EB (…) Dayyeh BKA et 2 al. in Obes Surg
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.